A detailed history of Two Seas Capital LP transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Two Seas Capital LP holds 8,387,388 shares of ABUS stock, worth $26.9 Million. This represents 10.86% of its overall portfolio holdings.

Number of Shares
8,387,388
Previous 8,571,751 2.15%
Holding current value
$26.9 Million
Previous $26.5 Million 21.92%
% of portfolio
10.86%
Previous 10.59%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.12 - $4.56 $575,212 - $840,695
-184,363 Reduced 2.15%
8,387,388 $32.3 Million
Q2 2024

Aug 14, 2024

BUY
$2.52 - $3.63 $1.84 Million - $2.65 Million
729,824 Added 9.31%
8,571,751 $26.5 Million
Q1 2024

May 15, 2024

SELL
$2.26 - $2.92 $2.71 Million - $3.5 Million
-1,200,000 Reduced 13.27%
7,841,927 $20.2 Million
Q4 2023

Feb 14, 2024

BUY
$1.69 - $2.54 $1.29 Million - $1.93 Million
761,109 Added 9.19%
9,041,927 $22.6 Million
Q2 2023

Aug 14, 2023

BUY
$2.24 - $3.06 $1.83 Million - $2.5 Million
816,094 Added 10.93%
8,280,818 $19 Million
Q1 2023

May 15, 2023

SELL
$2.23 - $3.1 $88,015 - $122,353
-39,469 Reduced 0.53%
7,464,724 $22.6 Million
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $3.53 Million - $5.27 Million
1,850,276 Added 32.73%
7,504,193 $17.5 Million
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $4.05 Million - $6.2 Million
2,152,041 Added 61.45%
5,653,917 $10.8 Million
Q2 2022

Aug 12, 2022

BUY
$1.98 - $3.17 $2.58 Million - $4.13 Million
1,302,807 Added 59.24%
3,501,876 $9.49 Million
Q1 2022

May 13, 2022

BUY
$2.42 - $3.98 $3.32 Million - $5.47 Million
1,373,500 Added 166.37%
2,199,069 $6.55 Million
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $2.57 Million - $3.81 Million
825,569 New
825,569 $3.21 Million

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $481M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Two Seas Capital LP Portfolio

Follow Two Seas Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Seas Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Seas Capital LP with notifications on news.